Dupixent® (dupilumab) is available under the High Tech Arrangement from 1 April 2021. A Managed Access Protocol is in place for dupilumab (Dupixent®). This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of dupilumab under the High Tech Arrangement.
The prescribing of dupilumab (Dupixent®) under the High Tech Arrangement is confined to consultant dermatologists who have agreed to the terms of the HSE-Managed Access Protocol and have been approved by the HSE-Medicines Management Programme.
The clinician must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.
A copy of the HSE-Managed Access Protocol for dupilumab and the application form for individual reimbursement approval can be found in the Related Files section below.